value innovationcontent company consolidated financial statement shareholder perspective key aspect overview select consolidated company corporate body consolidate balance sheet consolidate profit loss statement consolidate cash flow statement group management report statement change group equity information group note consolidated financial statement report economic position independent auditor report report opportunity risk report expect development financial highlight product human pharma net sale amount million eur indicate change jardiance net sale ofev family region million eur america million eur europe asiaaustraliaafrica aaa business trajenta spiriva human pharma jentadueto animal health million eur million eur biopharmaceutical contract manufacturing sale research development expense product personnel expense animal health net sale average number employee operate income operating income nexgard frontline net sale group profit million eur million eur group proft net sale group equity investment tangible asset ingelvac depreciation tangible asset heartgard circoflex flexcombo million eur million eur company make new well medicine human animal heart mission create breakthrough therapy change live independent familyowne boehringer ingelheim freedom pursue longterm vision look ahead identify health challenge future target area need good worldleading researchdriven biopharmaceutical company employee create value innovation human pharma animal health business boehringer ingelheim realize net sale billion eur investment billion eur drive innovation enable generation medicine save life improve quality life realize scientific opportunity embrace power partnership diversity expert lifescience community work accelerate delivery medical breakthrough transform live patient generation come boehringer ingelheim annual report shareholder perspective company shareholder perspective year bring positivity pandemic covid year people look forward meeting reconnecte company culture thrive inperson interaction unfortunately year bring war europe cause rise energy price sharp increase cost live geopolitical tension escalate despite uncertainty past year boehringer ingelheim able touch live grow portfolio potential new medicine approval come year company exciting opportunity profound lasting impact live people animal purpose transform live generation employee extraordinary effort demonstrate ambition innovation powerhouse give confidence able address unmet patient need year come enter optimism know boehringer ingelheim continue drive positive change healthcare commitment key success behalf shareholder committee like thank employee determination dedication sign christian boehringer chairman shareholder committeethe board manage director hubertus von baumbach jean scheftsik szolnok carinne brouillonmichel pairet michael schmelmer boehringer ingelheim annual report key aspect innovation drive boehringer ingelheim impact live new therapeutic solution able help people despite economic geopolitical headwind pharmaceutical industry significant progress help world bring covid pandemic halt raise awareness importance vaccine pandemic preparedness urgency fight antimicrobial resistance boehringer ingelheim important year determine let market uncertainty slow progress grow pipeline reach fda breakthrough designation fast track designation orphan drug designation launch spevigo monoclonal antibody treatment patient generalize pustular psoriasis receive approval treat symptomatic chronic heart failure patient jardiance addition provide evidence patient live chronic kidney disease significantly benefit jardiance deliver promise research result key medical area include oncology central nervous system retinal health metabolism currently pursue clinical proof new medical product seven year expect new medicine approval help address unmet need patient launch range new product animal onwards business perform deliver medicine help million patient human pharma see ongoing strong demand innovative medication lead jardiance product portfolio respiratory medicine ofev animal health business feel impact economic slowdown europe north america time lay groundwork range new product launch company key aspect key overall strong performance commitment employee early research product supply engagement stakeholder heart equally grateful successful scientific commercial partnership truly appreciate value support excitement grow pipeline success current portfolio patient animal alike make confident future energize transform live generation reach people benefit product sign sign sign hubertus von baumbach carinne brouillon michel pairet sign sign jean scheftsik szolnok michael schmelmer boehringer ingelheim annual report corporate body shareholder committee christian boehringer chairman shareholders committee christoph boehringer erich von baumbach isabel boehringer mathias boehringer prof andreas barner company corporate body board manage director advisory board hubertus von baumbach nikolaus von bomhard chairman board manage director chairman advisory board chairman supervisory board carinne knochebrouillon mnchener rckversicherungsgesellschaft member board manage director human pharma hagen duenbostel chief executive officer ceo michel pairet kws member board manage director innovation frank mastiaux chief executive officer jean scheftsik szolnok enbw energie badenwrttemberg member board manage director chairman advisory board sunfire gmbh animal health jan rinnert michael schmelmer ceo chairman board manage director member board manage director heraeus group finance group functions angela titzrath chairwoman hamburger hafen und logistik ags executive boardgroup management report information group group business model research development production employee report sustainable development generation report economic position macroeconomic environment earning position development business financial position net asset position report opportunitie risk opportunitie risk management individual risk overall statement risk situation report expect development boehringer ingelheim annual report group management report information group group business model boehringer ingelheim develop breakthrough therapy transform life today gen eration come independent family own pursue longterm vision identify challenge develop solution area medical therapeutic need patient unfulfille insufficiently address aim transform live patient generation goal inspire employee real significant contribution life human animal alike boehringer ingelheim stand innovation year strategic pillar longterm competitive investment innovation patient wellbeing maxim make researchintensive company germany sectors human pharma business mainstay activity account overall sale business area underpin innovative portfolio case prod uct standard treatment medicine research focus cardiovascular metabol disease oncology respiratory disease immunology disease central nervous system cns retinal health jardiance jardiance medicine treatment type diabetes reduce risk cardio new indication vascular disease type diabetic preexist cardiovascular condition heart failure group bestselle human pharma product net sale business human pharma million eur animal health group million eur biopharmaceutical million eur contract manufacturing million eur sale million eur group management report information group net sale region million eur americas europe asiaaustraliaafrica aaa begin jardiance approve fda european ema regulatory authority treatment heart failure preserve ejection fraction addition effectiveness jardiance chronic renal failure prove empakidney study ofev treatment rare respiratory disease idiopathic pulmonary fibrosis ipf increasingly indication systemic sclerosis interstitial lung disease sscild record strong growth product play significant role boehringer ingelheim success spiriva treatment chronic obstructive pulmonary disease copd asthma trajenta treatment type diabetes pradaxa prevent stroke patient atrial fibrillation prevention treatment thrombo embolic disorder milestone reach september approval spevigo substance spesolimab japan usa spevigo product ceive fda approval treatment generalize pustular psoriasis gpp rare lifethreat ene neutrophilic disease animal health business boehringer ingelheim lead provider vaccine thera peutic portfolio include product pet horse livestock swine rumi nant poultry core brand nexgard follow frontline heartgard foundation success pet segment product portfolio horse expand approval renutend europe renutend prove product enhance healing tendon suspensory ligament injury horse complement equine stem cell product boehringer ingelheim articell forte treat mild moderate recurrent lameness associate nonsep tic joint inflammation horse swine segment establish swine vaccine ingelvac circoflex treat porcine circovirus type important component company product portfolio boehringer ingelheim annual report biopharmaceutical activity comprise manufacture human pharmaceutical product actilyse metalyse praxbind spevigo world lead provider process development commercial production biopharma ceutical thirdparty industrial customer sale mainly comprise discontinue operation financial year achieve majority sale region america europe asiaaustraliaafrica aaa region include country china strategic significance group future development make sale research development goal research develop innovative medicine therapie treatment disease satisfactory treatment available aim relevant contribution area need treatment high human pharmaceu tical segment field animal health employ average people global crossdivisional research network billion eur present country central facility germany biberach ingel invest heim rhein usa ridgefield connecticut duluth georgia joseph missouri austria vienna japan kobe france lyon china shanghai tivitie location continue expand renew exist product portfolio order safeguard group organic longterm growth accordingly increase research development expense recent year past year growth outpace revenue trend total approximately billion eur invest new medicine level previous year correspond group net sale expense human pharma amount billion eur research development expense million eur net sale human pharma expense million eur human pharma net sale animal health expense million eur animal health net sale average number employee investment tangible asset million eur investment infrastructure group management report information group longterm collaboration academic institution public research institution biotech company pharmaceutical company integral work scientific field collaborate joint project academic institution span continent continuously expand accelerate portfolio cooperation license agreement acquisition longterm objective pipeline base external innovation way combine strength research partner strength acknowledge high scientific standard business development relationship forge year early investment boehringer ingelheim venture fund contribute significantly objective boehringer ingelheim confirm attractiveness partner new nership able strengthen pipeline basis example work lifebit biotech ltd biomedical data analytic provider build scalable data analytic infrastructure platform aim collaboration collect finding large exter nal biobank accelerate development new drug evotec biomrieux launch company aurobac therapeutic sas aim develop novel antibiotic precision therapy combat antimicrobial resistance amr new grant program partnership university tbingen germany aim explore new proache improve human animal health datum science method successful start initial joint development start collabora tion company click therapeutics inc develop digital health application digitale gesundheitsanwendungen diga prescribing patient schizophrenia combination drug therapy establish longterm partnership animal health business example collaborate biopharmaceutical company mabgenesis inc accelerate discovery development new monoclonal antibodie potential canine therapie research cooperation development smallmolecule therapy canine oncology initiate carthronix collaboration focus identify new molecule fight cancer dog form basic research start threeyear cooperation agreement goog field quantum compute digital transformation strategy partner ship aim harness computing power new technology usable boehringer ingelheim pursue innovation rapid precise manner conserve resource time digital lab expand capability development approval software medical device establish center excellence compa systematically expand external innovation network develop digital health product global market good example consanas cloud telligent digital platform stroke patient recently launch chinese market provide access stateoftheart rehabilitation measure consanas cloud support tients relative difficult journey everyday life digital diagno sis treatment method solution represent milestone development digital health product china boehringer ingelheim annual report site animal health human pharma bix digital lab americas europe asia usa belgium china ames iowa evergem beijing athens georgia shanghai germany colbert georgia taizhou biberach duluth georgia ingelheim rhein japan fulton missouri kathrinenhofrohrdorf kobe north brunswick new jersey ochsenhausen ridgefield connecticut joseph missouri france lyon boreal lyon porte des alpes saintvulbas netherlands lelystad austria innsbruck vienna switzerland basel geneva group management report information group boehringer ingelheim venture fund drive innovation investment young company carry research earlystage science technology venture fund invest biotech startup company innovative concept technology potential provide groundbreake new therapeutic platform venture fund create company identify research project university academic insti tutions establish venture fund asia alongside exist venture fund germany usa research institute molecular pathology imp vienna biomedical research institute group company boehringer ingelheim scientist approxi mately country imp conduct research molecular cellular mechanism form basis complex biological life process human disease imp lead institution kind late group leader receive prestigious grant award european research council erc seven group leader elect member european molecular biology organization embo open innovation platform opnmecom boehringer ingelheim contribute pro cess scientific collaboration pharmaceutical world molecule preclinical stage currently available academic researcher world free charge form collaboration enable new scientific finding field oncology example boehringer ingelheim activity preclinical clinical basis sustainable success group positive business development past year underpin organic process renew portfolio base activ itie inhouse supplement external cooperation partnership con tinue priority future high level innovation reflect pipeline fda breakthrough therapy designation btd btd novel experimental phosphodiesterase pdeb inhibitor confirm financial year decline lung function patient idiopathic pulmonary fibro sis ipf reduce help human pharma human pharma business contribute purpose transform live new generation achieve important milestone pipeline launch new indi active substance cation different disease area cardiometabolic disease oncology respiratory human pharma disease immunology disease central nervous system cns portfolio human pharma portfolio include overall clinical preclinical project base new molecule boehringer ingelheim annual report development pipeline end cardiometabolic disease phase glpfgf agonist phase heart disease modulator phase trpc inhibitor fsgs phase glpgcgr agonist nash phase glpgcgr agonist obesity phase sgc activator csph phase empagliflozin sglt inhibitor aldosterone synthase inhibtor ckd phase empagliflozin new indication sglt inhibitor post phase iii empagliflozin new indication sglt inhibitor ckd registration oncology phase bhcd tcell engager phase dllcd tcell engager phase cdfap agonist phase ezabenlimab antibody phase tki phase kisima cancer vaccine phase kras inhibitor phase mdmpantagonist phase vsvgp phase heterologous prime boost vaccine phase sirpantagonist phase pan kras sos inhibitor phase trailrcdhantibody phase mdmpantagonist ddlp phase respiratory disease phase ion channel inhibitor phase lysophospholipase inhibitor phase catc inhibitor ncfb phase pdeb inhibitor ppf phase pdeb inhibitor ipf phase iii group management report information group development pipeline end continue immunology phase antibody phase kinase inhibitor phase spesolimab ilr antibody phase spesolimab ilr antibody gpp flare prevention phase spesolimab ilr antibody gpp flare treatment registration central nervous system disease phase phosphodiesterase inhibitor phase digital therapeutic phase nmda regulator phase mdd phase bpd phase ptsd phase iclepertin glyt inhibitor cia phase iii retinal disease phase phospholipid modulator phase vascular modulator phase ischemia modulator dmi phase semaa antibody dmi phase investigate combination therapy key pipeline advance breakthrough therapy designation grant food drug administration partner project acquire asset prevention post approve europe china japan treatment generalize pustular psoriasis gpp flare adult indication abbreviation bpd borderline personality disorder ddlp dedifferentiate liposarcoma ipf idiopathic pulmonary fibrosis crohns disease dmi diabetic macular ischemia mdd major depressive disorder cia ognitive impairment associated fsgs ocal segmental glomerulo myocardial infarction schizophrenia sclerosis nash onalcoholic steatohepatitis ckd chronic kidney disease gpp generalize pustular psoriasis ncfb noncystic fibrosis bronchiectasis copd hronic obstructive pulmonary heart failure ppf progressive pulmonary fibrosis disease hidradentis suppurtiva ptsd posttraumatic stress disorder csph clinically significant portal hypertension boehringer ingelheim annual report cardiometabolic disease year begin indication extension empagliflozin adult suffer heart failure preserve ejection fraction ema fda approval base clinically prove benefit patient symptomatic chronic heart failure include preserve ejection fraction addition phase iii empakidney study stop early positive efficacy empagliflozin adults chronic kidney disease result study present asn congress show superior benefit empagliflozin patient chronic kidney disease ckd versus placebo submission marketing authorization new pagliflozin indication ckd regulator take place core market plan world wide result dinamo trial present idf congress show empagliflozin sglt inhibitor statistically significant reduction blood sugar level child adolescent type diabete complete phase trial glucagon receptor glp receptor dual agonist people obesity investigate phase trial people nash liver fibrosis aldosterone synthase inhibitor investigate phase trial combination empagliflozin people chron kidney disease type diabetes receive fast track designa tion fda october oncology oncology aspiration improve live people cancer deliver meaningful advance ultimate goal significantly sustainably improve life expectancy num ber type cancer long term robust pipeline homegrown license partner clinical asset diverse range mode action include cancer celldirecte immunooncology investigational therapy smart combination approach offer great benefit people live cancer start pivotal phase lllll trial mdmp antagonist socalle brightline trial investigate compare doxorubicin firstline treatment people advance dedifferentiate liposarcoma rare aggressive form liposarcoma fda grant orphan drug designation treatment soft tissue sarcoma brightline investigate drug secondline treatment people specific form biliary tract carcinoma pancreatic cancer respiratory disease focus boehringer ingelheim new therapeutic option people respiratory disease high unmet need ofev nintedanib treatment option idiopathic pulmonary fibrosis ipf slow decline lung function ofev approve treatment ipf country sscild systemic sclero sisassociate interstitial lung disease country pfild progressive fibrose interstitial lung disease country publish result inpedild trial group management report information group investigate dose safety profile nintedanib child adolescent base finding regulatory application submit european medicine agency follow submission fda accept nintedanib approve treatment pediatric patient fibrose interstitial lung disease address high unmet need underserved patient population despite advance therapy new treatment urgently need complement exist therapy help stop slow disease progression company report promising week phase trial datum novel investigational phosphodiesterase pdeb inhibitor show reduction rate lung function decline patient idiopathic pulmonary fibrosis ipf potential new treatment build leadership lung fibrosis investigate phase iii pivotal clinical trial initiate fibroneeripf patient idiopathic pulmonary fibrosis fibroneerild people live progressive fibrose inter stitial lung disease immunology immunological disease greatly impact patient live physically psychologically boehringer ingelheim dedicate discover develop firstoftheirkind therapie inflammatory disease deep understand molecular pathway pioneer scientific breakthrough target repair prevent inflammatory disease skin gut joint spesolimab market spevigo advanced immunological compound current boehringer ingelheim pipeline receive approval major market treatment gpp flares adult receive marketing authorization fda ema china japanese authority approval base positive phase data effisayil trial central nervous system disease boehringer ingelheim evolve mental health research enable people thrive people mental health condition carer benefit treatment experience provide predictable outcome approach link behavior underlie neurobiology develop target therapy innovative approach digital therapeutic strive enable people mental health condition create mean ingful connection live love one society example approach currently investigate clinical phase trial people live borderline personality disorder posttraumatic stress disor der major depressive disorder receive fasttrackdesignation fda posttraumatic stress disorder addition borderline personality disorder complete phase trial compound indication january boehringer ingelheim annual report animal health line abovementione goal operating area high medical need con centrate animal health discovery development highly innovative treatment preventive therapy thing include therapeutic oncology munology new chemical entity new method control counter resistance parasite new tool technology improve prevention infectious disease current portfolio include innovative vaccine parasiticide protection pet livestock pharmaceutical product treatment chronic disease research increasingly incorporate new approach technology use stem cell monoclonal antibodie innovation strategy build scientific approach investigation cause mechanism disease multiple animal specie lead discovery new way mitigate causes intervene disease process focus area infectious disease noninfectious disease parasiticide work use experience human pharma research external partner area outside animal health site organize regional innovation center locate usa europe china ensure concentration critical mass expertise need deliver therapie customer key geography designate site region serve focus specific segment overall strategy footprint strengthen local execution facilitate regional external network partnership synergies key advantage boehringer ingelheim retain human pharma animal collaboration health division team human pharma animal health work share knowl human pharma edge specific disease mechanism chemistry compound cut edge technique animal health previous year successfully introduce product aservo equihaler semintra result synergies human pharma animal health team additional promising compound pipeline expect innova tion connection particularly area therapeutic external collaboration play key role initiate new strategic partnership include partnership carthronix biopharmaceutical company focus develop small moleculebase therapy degenerative agingrelate disease collaboration focus identify new molecule target cancer dog boehringer ingelheim test select group small molecule provide carthronix goal determine impact canine cancer enter partnership mabgenesis inc private bio pharmaceutical company headquarter yokohama japan collaboration aim discover innovative canine therapeutic antibody mabgenesis inc platform technology furthermore continue work key research institution globe develop new solution unmet medical need example effort develop effective approach prevent african swine fever continue cause massive loss pig population lead partnership friedrichloefflerinstitut pirbright institute oxford university initiate research development clinical study worldwide award product registration key new approval include renutendtm europe new stem cell therapy improve heal tendon suspen sory ligament injury horse vetmedinca usa receive conditional approval new fda procedure drug delay onset canine congestive heart failure dog preclinical myxomatous mitral valve disease europe country group management report information group middle east receive approval fencovis new vaccine prevent calf diarrhea fencovis provide passive immunity calf maternal colostrum obtain approval new product new area application expand geographic scope sale activity exist product additional important aspect activity production human pharma human pharma business globally active production facility responsible steady supply topquality medicine patient ongoing development company internal production facility strategic cooperation external manufacturer establish modern flexible market supply network encompass entire value chain supplier start material worldwide logistic distribution finish phar maceutical product boehringer ingelheim production facility focus product strategically important company stateoftheart manufacture technolo gy time partnership external manufacturer add specialist technology production network available inhouse expand production capac ity standard technology product high capacity requirement reach advanced point life cycle financial year global network include boehringer ingelheim plant country group biopharmaceutical facility facility manufacture pharmaceutically active substance produce medical device finish pharmaceutical product manufacture package facility past year present particular logistical challenge ongoing effect covid pandemic effect russiaukraine war boehringer ingelheim able ensure steady supply medicine patient alongside use appropriate safe stock possible thank establishment key manufacturing step tech nologie multiple facility different geographical region case strengthen resilience concept link supply chain significant contribution development supply security progress digital trans formation production network entire supply chain control value chain supplier customer endtoend optimize great implementation supply chain strategy use digital automate process technology enable high level transparency efficient control global production network supply chain boehringer ingelheim annual report production facility animal health human pharma bio iopharmaceutical contract manufacturing america europe asia brazil belgium greece china itapecerica evergem koropi nanchang paulnia shanghai bio denmark great britain taizhou mexico kalundborg pirbright guadalajara indonesia germany italy xochimilco bogor biberach bio fornovo puerto rico dortmund noventa japan barceloneta ingelheim rhein yamagata austria usa france vienna bio athens georgia grand lyon industrial spain fremont california bio biologic center sant cugat gainesville georgia toulouse joseph missouri compose site lyon portedesalpe lentilly jonage group management report information group delivery capability patient care priority boehringer ingelheim company consistently make important investment development transformation produc tion capacity chemical pharmaceutical network ingelheim rhein head quarter key investment flexible plant industrialization newly develop inno vative medicine initial market supply fully execute expansion production technology capacity active pharmaceutical substance ingelheim rhein germany fornovo italy site pharmaceutical bulk good finish medicinal product sant cugat spain koropi greece site initiate push forward sustained manner ensure supply antidiabetic particular jardiance pipeline product operational activation biopharmaceutical largescale cell culture production building vienna facility represent milestone expansion capacity network newly develop product strengthen bio pharmaceutical business global quality vision quality safety successfully implement help global quality transformation program transformation sign year quality process system strengthen prepared future requirement quality manifest competitive advantage important contribu tion cultural transformation rollout highly develop quality culture patient focus action employee actively contribute animal health animal health product manufacture network production facility country addition company facility contract manu facturer manufacture medicine boehringer ingelheim product portfolio essentially animal health consist vaccine pharmaceutical product nutraceutical successfully expand production facility launch innovative packaging technology twistpak chemical medicine country vaccine supplement stem cell therapeutic diagnostic product monitoring solution include digital application livestock monitoring link livestock owner veterinarian boehringer ingelheim investment inter alia expand capacity topselle product group nexgard barceloneta puerto rico site manufacturing capacity jonagelyon france continue include construction modern plant vaccine high biological safety standard production network optimization begin advanced objective reliable efficient delivery product biopharmaceutical contract manufacturing boehringer ingelheim perform biopharmaceutical activity facility biberach lead germany vienna austria fremont california usa shanghai china comprise biopharma provid manufacture ownbrand marketable product actilyse metalyse ers industrial praxbind spevigo biopharmaceutical clinical testing boehringer ingel customer heim world lead company process development launch preparation commercial production biopharmaceutical thirdparty industrial customer pharmaceutical company innovative biotech firm client bio pharmaceutical contract manufacturing business boehringer ingelheim cover entire bio pharmaceutical value chain regard development production cell mammalian cell microorganism production process manufacture active substance finish pharmaceutical product product launch global market supply boehringer ingelheim annual report capacity utilization network industrialscale production facility remain high level maximum production volume actilyse reach bibe rach site inhouse process transfer new largescale cell culture facility vienna carry establish market product future product manufacture parallel boehringer ingelheim site way optimally use advantage global biopharmaceutical production network ensure reliable connection patient furthermore boehringer ingelheim ilr monoclonal antibody spesolimab trade spevigo successfully launch biberach site september build balanced latestage commercial product portfolio microbial production facility vienna despite challenge external situation associate covid cell culture plant biberach shanghai fremont microbial production vienna continue manufacture deliver biopharmaceutical reliably patient worldwide employee report boehringer ingelheim employ people average worldwide represents increase previous year average number employee region americas europe asiaaustraliaafrica aaa commit employee identify company aim find work atmos phere boehringer ingelheim positive appreciative major success factor driv ing group positive growth high level personal commitment day help fulfill joint promise ensure supply vital medicine annual global employee survey provide relevant feedback enable continuously improve work environment boehringer ingelheim success base innovation presence country global nature value chain international nature clientele stringent wideranging requirement national regulator demand great flexibility organiza tion convince relationship base trust mutual openness respect empathy value strong competitive diversity think spirit inclusion relationship promote capacity innovation area business boehringer ingelheim convince future hold unique opportunity innovation sustainability well health companywide purpose transforming live generation expression ambition create well future upcoming generation unite order optimally equip employee future require ment constantly change health labor market lifelong learning group management report information group development personnel priority corporate strategy addition access external offer employee worldwide linkedin learn online lan guage provider gofluent company establish businessarea topicspecific academy early objective building require skill internally focus manner example data science academy open november univer sity medicine excellence found july data science academy target group beginner datum expert find tailormade learn opportunity use datum analysis respective area responsibility employee train internally field datum datum science employee medical discipline take university medicine excellence threemonth inaugural program accelerate program develop roll renowned harvard medical school important cornerstone develop specialist tomorrow train pro gram different scientific technical commercial training course cooperative study program company offer young people opportunity start profes sional life average young people worldwide enrol boehringer ingelheim vocational training program total young people start german loca tions boehringer ingelheim selection training cooperative study program closely coordinate discipline ensure curricula training program meet need company important objective strengthen appeal boehringer boehringer ingel heim employer addition attractive career path boehringer ingelheim offer ngelheim additional benefit workforce include range company pension plan flexible ecognize homebase work option numerous healthrelated benefit company global recognition employer auditor international inde employer pendent employers institute institute rate company particularly globally area business strategy value ethic integrity boehringer ingelheim place competitor overall average especially area reward recognition addition independent institute highlight area diversity inclusion onboarde sustainable development agile working method see growth year award key country region make global employ employer worldwide hold title addition germany boehringer ingelheim award argentina australia austria brazil chile china colombia ecuador france great britain hungary indonesia italy malaysia mexico netherlands new zea land philippine poland romania russia saudi arabia singapore south korea spain thailand united arab emirates vietnam boehringer ingelheim annual report sustainable development generation sustainable sustainability firmly anchor corporate philosophy boehringer ingel evelopment heim found understand awareness sustainability develop strategy generation continue influence decisionmake action focus human animal health boehringer ingelheim position address interconnect sustainable development challenge subsequently provide relevant contribution healthier sustainable future sustainability strategy entitle sustainable devel opment generation base follow pillar health good health people animal potential good health community people green good health planet pillar boehringer ingelheim implement initiative globe drive company contribution impact alignment united nations sustainable development goal base year aim achieve follow concrete measurable goal health expand access healthcare additional million people vulnera ble community invest billion eur health innovation research tackle non communicable disease additional million eur partnership combat emerge infectious disease potential aim positively impact million people vulnerable community empower support employee partner innovative social entrepreneur green carbonneutral company operation scope significantly reduce resource footprint value chain period despite grow business activity health good health people animal health health follow ambition develop well therapy enable well solution focus global healthcare challenge pillar include number project initiative reflect health people diversity patient expertise partner include animal access healthcare access healthcare initiative seek improve healthcare vulnerable community disease awareness diagnosis effective prevention care availability medicine achieve milestone include expand access healthcare develop region defeatncd nership publicprivatepeople partnership envision universal health coverage noncommunicable disease ncds boehringer ingelheim join defeatncd partner ship currently collaborate interconnect pillar national ncd capacity building community scaleup ncd service affordability accessibility essential ncd supply finance countrylevel ncd programming coun try focus india gambia rwanda djibouti world health summit october boehringer ingelheim partner discuss progress improve care patient ncds collaboration partnership group management report information group access healthcare initiative offer comprehensive program patient screen followup program start kenya screen referral chronic obstructive pulmonary disease copd follow patient enrollment access spiriva tiere price achieve equitable access support adherence patient low income pathway indigenous health collaboration project canada aim impact live member indigenous community address high prevalence certain noncommunicable disease ncd community pro gram establish indigenousle indigenousinforme sion close health gap experience indigenous community focus relationship build positive sustainable future partner currently pilot project underway british columbia alberta manitoba nova scotia tai lore individual need respective community similarly initiative collaboration healthcare professional patient advocacy group national pharmaceutical management agency assist indigenous community new zealand equitable access new type diabetes medication collaborate expert ngos global alliance rabie control garc set pilot mass vaccination program dog intent design new model scale rabie elimination sustainably effort aim fight rabie vulnerable community endemic country control rabie animal help reduce human death toll disease stop rabie pilot initiative launch south africa effort enable sustainable dog vaccination campaign vulnerable community boehringer ingelheim vaccinate dog collaboration khula outreach program south africa partner local government tackle rabie angel angel initiative aim improve stroke care worldwide additional clin ics doctor nurse paramedic join network angel initia tive big stroke community world include healthcare professional hospital country helped ensure estimate million patient treat line define standard product donation product donation aim complement boehringer ingelheim access healthcare effort provide medicine vulnerable community access product donation reach patient country world wide include product donation million eur patient ukraine lastmile lastmile initiative launch stretch subsaharan africa reach smallholder farmer kenya cameroon nigeria mali burkina faso ethiopia enable product registration initiative aim train smallholder farmer vulnerable community prevention animal disease leverage access healthcare solution vaccine treatment optimize health productivity livestock boehringer ingelheim annual report potential good health community people potential potential focus provide health good possible condition focus people people boehringer ingelheim community partner reach community potential safe safe program establish place particular emphasis importance ensure safe workplace employee partner continu ously review optimize work safety culture global network safety pert strive maintain employee good health preventing incident accident occupational health risk communicate regularly internally management col league partner community global level ambition successfully transform organization drive enforcement rule create corporate culture safety embed create value people bring safety culture mindset high safety initiative create address frequent safety concern offer support employee stay safe lead example encourage daily work life furthermore boehringer ingelheim official partner euo sha healthy work place lighten load campaign prevent work relate musculoskeletal disorder msds continue healthy healthy program establish well support employee additional knowledge tool resource maintain necessary improve health wellbeing workplace program define set global health wellbeing stan dard implement international network health wellbee ambassador health navigator foster healthy company culture promote strong awareness physical mental health healthy habit diversity equity inclusion dei core value empathy respect passion trust foster diverse collabora tive open inclusive work environment key innovation value creation sustainable growth boehringer ingelheim convince value diversity foster inclusive environment right thing people community smart thing business help well understand fulfill different need patient customer partner globe organizationally enable aim open collaborative inclusive culture corporate dei office dei champion globe represent different country region global culture dei council boehringer ingelheim promote social wellbeing encourage employee resource group erg network company erg network voluntarily form leadership sponsor erg woman tech found member aim connect empower woman work ing technology boehringer ingelheim group management report information group furthermore company enable employee raise voice case potential noncompliance speak procedure pursue mediation bias inequity system process practice boehringer ingelheim continue train leader employee unconscious bias inclusive behavior etraining complete december masterclass program integration dei employee onboarde leadership development program etraining hold time language addition german english human right boehringer ingelheim continuously step effort area human right ethic approach align united nations guide principle business human right human right embed company culture underline human right environmental health safety sustainability policy human right integrate business code conduct supplier code conduct environmental health safety ehs compliance program continue focus implementation component require forthcoming german supply chain diligence law go effect january make health boehringer ingelheim ashoka world large network social entrepreneur jointly establish make health mmh initiative longterm partnership focuses enable innovative solution tackle complex healthcare challenge people animal community approach link interdependent issue economic development infrastructure education culture healthcare issue emphasize collabo ration community equal partner engage boehringer ingelheim employee share knowledge skill mmhs individual initiative form holistic continuum generate impact level support vulnerable community finance social enterprise highlight include social innovation date social entrepreneur worldwide work area human animal health support community activation program establish india sub saharan africa prove groundbreake reach people reach include clean water hygiene project implement innovative farming model provide animal health business skill train course inclusion program marginalize community group people albinism support social business support social enterprise make health business accelerator program join program cooperation partner villgro afrika social enterprise focus animal health accept new incubation program rise star program assist social startup subsaharan africa financial mean management skill employee engagement accelerate scaleup sustain business model boehringer ingelheim annual report make health convention twoday hybrid event ingelheim germany nairobi kenya bring participant industry govern ment civil society academia social entrepreneurship impact financing connect collab orate innovate achieve sustainable solution press healthcare issue make health focus social entrepreneurship innovative approach solve healthrelate challenge boehringer ingelheim social engagement impact engagement fund leverage innovative financing tool grant funding donation intention continue support amplify social impact sustain scalingup social business subsaharan africa aim create portfolio comple mentary social business address healthcare challenge cowtribe inc lead lastmile veterinary delivery company ghana announce investment recip ient cowtribe support farmer remote region ghana ensure supply essential vaccine animal investment intend reach significantly farmer animal support green health planet green healthy planet prerequisite healthy people animal communitie environmental focus challenge see isolation interconnect tangible nvironment effect health entire society subsequently sustainable use natural resource apply ecodesign green chemistry concept promotion strong environ mental awareness key component environmental sustainability program order help protect health current future generation safeguard prospect healthy future green fund support internal project area circular economy decarbon ization water management provide fund new environmental project worldwide boehringer ingelheim pay particular attention environmental sustainability aspect major project set aside additional million eur purpose boehringer ingelheim pharmaceutical company receive greencanteen certification sustainable catering concept ingelheim head quarter build dortmund site certify currently total corporate canteen receive certification germany belong boehringer ingelheim carbon footprint continuously work reduce greenhouse gas emission commit carbon neutral company operation scope newable electricity continue substantial investment sustainable technology tool process introduction internal carbon price eur ton create additional economic incentive green innovation example activ itie reduce greenhouse gas emission include group management report information group new certification carbon neutrality site kathrinenhofrohrdorf germany gainesville georgia usa shanghai china total site addition dort mund germany sant cugat spain transition renewable electricity solution numerous location include site austria germany spain usa year company share renewa ble electricity purchase worldwide increase construction new solar plant headquarters ingelheim near completion initiation supplier collaboration program key supplier intention reduce emission value chain scope performance measure digital platform continue partnership climateseed support reforestation project africa canada china india indonesia germany offset unavoid able carbon emission strengthen biodiversity protect drinking water resource use circular economy aspect implement stage value chain minimize waste apply eco design green chemistry concept new product continuous opti mization measure reduce annual volume waste landfill resource use increase recycling reuse rate optimize environmental footprint future boehringer ingelheim product specifically integrate criterion sustainability design product phase product lifecycle innovation unit work reduc ing environmental footprint medicine approach utilize principle ecodesign green chemistry global organization start synthesis drug substance package product achieve milestone include establish green grant program aim accelerate sustainable science technology innovation academic collaboration create new option ecodesign launch research challenge open innovation platform openme launch green award recognize outstanding implementation green chemistry green engineering ecodesign concept demonstrate compelling environmental health safety efficiency improvement win team award iucon conception ecodesign playbook well evaluate implement ecodesign green chemistry criteria pharmaceutical development water stewardship access clean water major impact social cultural justice environmental sustain ability local economy reason boehringer ingelheim implement program late water relate risk production site site establish water scarcity area implement water stewardship program alliance water stewardship aw production site fremont california usa receive aws certification second site follow aws certification promeco production facility xochimilco mexico boehringer ingelheim annual report furthermore evaluate wastewater production site possible resi due active pharmaceutical ingredient api trace substance basis clean water initiative ensure trace pharmaceuticals wastewater remain signifi cantly effect level initiative collaborate industrial network sup plier encompass entire value chain context boehringer ingelheim enable joint project initiative make health kenya aim improve access clean water example construc tion solarpowere water tower store water nearby kibisi dam water dis penser station provide water distribution public facility private home pro ject estimate positively impact live people local community group management report report economic position report economic position macroeconomic environment global economy face immense economic challenge accord international monetary fund imf global economic growth fall russia war aggression ukraine associate sanction impose russian prod uct lead sharp increase gas energy price begin continue course year significant restriction place russian natural gas supply time electricitygeneration cost gasfire power plant rise lead significant price increase electricity market high energy price result high production cost company lead reduced purchasing power private house hold company force reduce energy intensity shortage good rise energy price significant driver global increase inflation global pharmaceutical market exclude covid vaccine grew grow human eur trillion year correspond compound annual growth pharma market year source iqvia particularly case pharmaceutical market con allow increase trast sector tends characterize long term performance investment tional economy particular demographic respective society addition average growth market influence constant improvement global access medical care russias war aggression ukraine indirectly lead high energy production cost pharmaceutical company boehringer ingelheim sale price regulate change high rate inflation lead interest rate hike numerous country central bank increase financing cost great volatility currency market time government regulatory program combat inflation adopt country direct impact pharmaceutical industry impact future financial year inflation reduction act ira particularly noteworthy regard effect covid pandemic continue negative impact negative eco nomic impact covid pandemic mean fully overcome internation supply chain disruption continue affect industrial production china restriction temporary lockdown negative impact demand medi cine time cost combat covid pandemic lead high additional burden healthcare system country order address challenge healthcare system expand use costcontainment tool mandatory price reduction pharmaceutical product external price reference system lengthy complex negotiation process delay access innovative new medicine patient increasingly involve cover cost treatment different copayment model germany saving plan politician healthcare system implement gkv statutory health insurance financial stabilization act gkvfinanz stabilisierungsgesetz specification increase cost pressure pharmaceu tical company reduce willingness invest germany pharmaceutical company participate vpa voluntary scheme brand medicine pricing boehringer ingelheim annual report access pay high reimbursement health authority increase health care spending repayment rate increase rate set measure increasingly put pressure pharmaceutical company limit future ability invest development new treatment option pro vide innovative medicine pharmaceutical industry work closely government public health authority meet challenge order ensure improve access medicine sustainable manner reduce delay market approval provide patient innovative medicine important prerequisite achieve objective remain reliable legal framework promote innovation ensure protection intellectual property tendency level aim weaken incentive instrument send wrong signal cuttingedge research investment pharmaceutical innovation competitiveness decline difficult european patient participate clinical trial access new innovative therapy animal health animal health market consist pet livestock segment continue growth market continue trend compare previous year growth slow reporting period par positive growth ticular consumer behavior adjustment response high inflation supply chain trend issue longterm driver growth population growth rise standard live people growth market increase life expectancy animal constant improvement veterinary care pet increasingly see life companion health important owner reflect increase demand product pet segment livestock segment benefit increase demand animal protein continuous growth consumer awareness regard highquality product increase prevalence zoonotic disease infectious disease transmissible animal mans human animal reinforce importance animal health industry general consolidation merger customer ongoing lead creased competition future growth animal health business largely drive therapeutic innovation order grow market investment need continuous sustainable competitive accord imf global economic growth forecast imf represent significant slowdown global economic growth accord oecd imf inflation remain high expect decline country global inflation project ease accord imf numerous additional risk significant impact economic growth mis calculation monetary policy low inflation high energy food price lead inflation last long furthermore tight financing condition significant impact company emerge market debt economic growth hamper new global health fear renew effect covid addition ongoing crisis china real estate sector affect domestic banking sector growth china involve crossborder implication furthermore global supply chain manently impair geopolitical fragmentation consequently cooperation climate policy difficult addition ongoing climate change increase risk occurrence natural disaster related health economic impact group management report report economic position currency development boehringer ingelheim global presence mean currency trend influence financial formance dollar usd japanese yen jpy chinese renminbi cny particularly worthy note extraordinarily high inflation prompt federal reserve particular significantly raise key interest rate support appreciation usd currency low eurusd february beginning year dollar fluctuate end year low high eur usd october japanese yen fluctuate high eurjpy january low eurjpy november chinese renminbi start year eurcny january high achieve midyear eurcny july low reach end year eurcny december significant transactional currency risk hedge suitable currency instrument currency development effect net sale average rate basis eur million eur dollar japanese yen chinese renminbi earning position boehringer ingelheim stable competitive financial performance solid financing basis independence make focus action basis imple ment corporate purpose transforming live generation invest innovation competitive scale make contribution improve human animal health innovative therapy boehringer ingelheim continue positive growth trend generate net sale million eur correspond increase compare previous year revenue million eur exchange rate effect positive impact reve billion eur nue development adjust effect group growth net sale net sale region million eur currency change adjust americas europe asiaaustraliaafrica aaa boehringer ingelheim annual report achieve net sale growth region previous year net sale mil lion eur share overall sale america region boehringer ingelheim key sale market growing currencyadjuste furthermore net sale growth region europe improve past financial year currencyadjuste sale include global license business amount million eur correspond share group sale positive trend drive global censing business allocate region market germany spain countries eastern europe asiaaustraliaafrica aaa region net sale increase currencyadjuste million eur key figure million eur change net sale operating income return net sale income taxis income taxis significant increase net sale product jardiance family ofev material ratio take account change inventory fall personnel expense rise aboveaverage rate alongside addi tional employee area research development medicine strategically important boehringer ingelheim production biopharmaceutical medicine adjustment pension inflation expectation pension trend currency effect amortization intangible asset depreciation tangible asset million eur higher compare previous year particularly attributable impairment loss intangible asset impairment loss acquire project risk inherent researchbase pharmaceutical industry development innovative medicine addition schedule depreciation amortization increase continue high investment activity currency effect financial year operating result increase slightly million eur positive operating development compare previous year despite increase cost high impairment loss nonreoccurre charge please development busi ness net sale provide basis sustainably invest able crease expense percentage sale approximately financial year basis return net sale fall high price procurement market increase number employee strategically important area investment financial income decline primarily development stock market impact budget asset pension similar obligation loss allowance nonconsolidate investment reduce hold income income taxis fall million eur despite slight increase operating result group management report report economic position income taxis fall million eur slightly high tax rate note regard provision german commercial law shareholder personal taxis aris ing group business activity recognize tax expense instead taxis present withdrawal group equity take specificity count actual tax burden markedly high figure show profit loss statement consolidated profit million eur overall financial year year positive corporate development boehringer ingelheim cost increase nonreoccurre charge largely offset positive business development despite challenge market billion eur condition group profit development business past year boehringer ingelheim activity divide human pharma animal health biopharmaceutical contract manufacturing business net sale business million eur currency change adjust human pharma animal health biopharmaceutical contract manufacturing sale human pharma human pharma business product available patient thank new approval additional country strengthen establish product million patient treat product human pharma business mainstay boehringer ingelheim activity account share group net sale net sale human pharma business increase currencyadjuste financial year million eur growth mainly drive establish product jardiance family ofev grow volume license business particular skyrizi license abbvie responsible marketing product key con tribution positive development human pharma business boehringer ingelheim annual report human pharma net sale product million eur currency change adjusted jardiance family ofev trajenta jentadueto spiriva pradaxa jardiance product high net sale jardiance addition treat ofev drive growth ment type diabete treatment chronic heart failure jardiance family generate net sale million eur currency adjust high previous year ofev second large product net sale primarily treat idiopathic pulmonary fibrosis indication sscild pfild ofev record net sale million eur achieve growth rate currency adjust previous year trajenta jentadueto treat type dia bete achieve revenue growth net sale increase currencyadjuste million eur product spiriva treat chronic obstructive pulmonary disease copd asthma develop line product life cycle net sale million eur level previous year currencyadjuste currency reason net sale anticoagulant pradaxa decline line product life cycle fell currencyadjuste compare previous year net sale million eur pradaxa continue boehringer ingelheim topselle medicine financial year increase net sale currencyadjuste achieve license income skyrizi product market globally partner abbvie base substance risankizumab largely develop boehringer ingelheim treat moderate severe plaque psoriasis psoriatic arthritis additionally med icine approve market treatment moderately severely active crohns disease sale volume financial year reflect related non reoccurre milestone payment human pharma business achieve growth region yearoveryear term regional distribution revenue usa remain strong revenue contributor growth rate currencyadjuste million eur represents share human pharma businesss overall net sale group management report report economic position achieve net sale million eur eucan region europe canada growth rate currencyadjuste eucan region generate sale share compare previous year company emerge market register improved volume sale past finan cial year growth rate currencyadjuste overall net sale country rise million eur doubledigit growth generate com pare previous year market china remain challenging vol umebased procurement mechanism covid lockdown able record slight sale growth compare previous year currencyadjuste favorable exchange rate japan account approximately total net sale human pharma business net sale fall currencyadjuste million eur significantly weak japanese yen compare euro human pharma net sale region million eur currency change adjust usa eucan emerge market japan animal health past financial year animal health business achieve revenue total mil lion eur provide group revenue animal health able increase revenue currencyadjuste support currency effect animal health net sale product million eur currency change adjust nexgard frontline heartgard ingelvac circoflex flexcombo topselle animal health medicine come pet business antiparasitic nexgard record sale growth currencyadjuste million eur remain highestselle product family portfolio animal health division financial year growth product nexgard spectra nexgard combo nexgard family topselling brand animal health industry able reach milestone billion eur sale boehringer ingelheim annual report contrast antiparasitic frontline medicine heartgard record decline net sale increase competition high inflation force pet owner prioritize household budget particularly usa significant influence decline sale observe ingelvac circoflex swine vaccine net sale fall currencyadjuste million eur mainly difficult market environment china animal health able exceed previous year net sale region essentially attribute currency effect usa grow currency adjust able compensate decline sale swine egment particularly pet segment include horse slight increase sale achieve eucan region sale ukraine russia fall short expectation war supply difficulty weigh pet poultry business europe overall net sale growth eucan region currency adjust alamea asia latin america middle east africa region register sale growth currencyadjuste sale pet segment high livestock segment sale tcm chinese market region fall currencyadjuste com pare previous year decisive factor decline zerocovid poli china combine numerous lockdown second difficult market swine segment characterize high feeding husbandry cost low sale price income swine producer result significantly demand medication prevent disease swine segment animal health net sale region million eur currency change adjust usa eucan alamea tcm biopharmaceutical contract manufacturing continue strong biopharmaceutical contract manufacturing business revenue currency growth adjust high previous year strong demand business biopharmaceutical ner market product order situation entire business develop positively contract result high level capacity utilization addition focus product manufacturing process transfer new production facility vienna salesdiscontinue operation discontinue operation aggregate activity minor strategic importance boehringer ingelheim net sale decrease expect group management report report economic position financial position boehringer ingelheim financial management strategy aim safeguard company financing mean operate cash flow far possible minimize financial risk optimize cost capital cash inflow operating activity million eur despite buildup inventory provide safe care patient revenuerelate buildup receivables positive business development significantly higher previous year million eur core business provide basis ability continue invest strategic business development investment total million eur fully finance operate cash flow million eur financial fund cash flow operating activity cash flow investing activity cash flow financing activity change financial fund cash relevant transaction change financial fund exchange rate movement valuation adjustment financial fund germany million eur invest biberach ingelheim location high capital past financial year addition strengthen biopharmaceutical expenditure volume location vienna million eur enable business development field animal health boehringer ingelheim invest construction modern plant vaccine high biological safety standard total investment project million eur approximately million eur pay past financial year cash outflow investing activity take asset sale account mil lion eur total follow disbursement financing activity million eur change exchange rate movement measurement adjustment group financial fund decrease million eur million eur million eur boehringer ingelheim annual report net asset position million eur change change asset intangible tangible asset financial asset fix asset inventory trade account receivable receivables current asset security cash cash equivalent current asset asset total asset equity liability group equity provision pension similar obligation tax provision provision account payable loan thereof residual term year liability liabilitie difference capital consolidation total equity liability december boehringer ingelheim total asset amount million eur increase million eur compare previous year increase primar ily high work capital trade receivables inventory positive curren effect million eur increase balance sheet item tangible asset increase million eur result renew high level investment activity particular strategic expansion business area bio pharmaceuticals austria germany human pharmaceutical research germany animal health france usa positive currency effect intangible asset decrease significantly amortization fund previously hold cash invest shortterm investment invest longterm security financial asset increase result result investment shareholding group management report report economic position work capital inventory trade receivable increase buildup stock ensure security supply high acquisition production cost price increase procurement market currency effect trade account receivable increase result reportingdate revenuerelate circumstance primarily usa germany increase receivables asset factor increase tax prepay ment positive currency effect asset increase higher defer tax asset result temporary difference measure consolidated company tax balance sheet measure consolidate balance sheet pension provision particular currency effect equity amount million eur december decrease slightly million eur result withdrawal include withdrawal financing boehringer ingelheim foundation tax payment boehringer ingelheim equity ratio foundation nonprofit foundation promote excellence basic research natural life science accord applicable commercial law regulation shareholder tax payment attributable group activity show profit loss statement tax expense withdrawal equity ratio fall slightly mainly increase total asset approximately december addition equity pension provision longterm liability available group capital long term item total million eur december represent share total asset consequently previous year longterm disposable capital continue cover intangible asset tangible asset work capital pension provision increase germany reduction discount rate adjustment provision current development inflation cur rent assumption pension trend usa low market value plan asset increase provision correlate change level revenue include provision discount usa commission royalty pay ment currency effect lead increase provision increase liability stem exclusively trade payable positive currency effect thirdparty debt duce liability decline mainly release difference arise capital consolidation defer income financial position likewise reflect boehringer ingelheim healthy economic development financial year boehringer ingelheim remain soundly finance company make considerable capital expenditure development business research activity resource order ensure longterm growth independence boehringer ingelheim annual report report opportunitie risk opportunitie risk management assess risk context holistic opportunity risk management endeavor account result opportunity opportunity management base strategy objective company indi vidual business operate business unit integral groupwide planning management system responsible business function bear direct responsibility early systematic identification analysis use opportunity researchdriven biopharmaceutical company boehringer ingelheim current research development activity definition consider opportunity relevant project outline research development chapter digital trans formation opportunity new possibility use technology area research development especially clinical development support patient therapy digital transformation particular importance sale admin istration aim risk management system implement boehringer ingelheim identify businessspecific risk particular risk jeopardize continued existence company early possible assess reduce reasonable level mean suitable measure person responsible key business function include process calculate assess risk groupwide risk information system ensure identify risk carefully analyze assess follow appropri eat classification adequate risk management measure initiate implementation systematically monitor year review internal audit department perform target routine audit extraordinary audits world addition adherence legal requirement internal group guideline main focal point functionality system fectiveness internal controls prevention loss asset efficiency struc ture process correspond adjustment optimization initiate necessary individual risk key risk boehringer ingelheim expose broken follow specific category financial risk legal risk information technology risk production environmental risk personnel risk industry risk risk identify concrete appear controllable mean specific management procedure term abstract case risk completely control mean target management procedure regardless probability occurrence group management report report opportunity risk financial risk relevant financial risk turn break follow currency risk geopolitical risk credit countryspecific risk financial investment shareholding risk currency risk global orientation business activity subject risk opportunity exchange rate volatility relation dollar japanese yen regard emerge market currency especially chinese renminbi group monitor quantifie risk regular interval make predictable future business relevant hedging strategy appropriate financial instrument forward exchange contract resultant risk subsequently designate concrete controllable limited geopolitical risk business boehringer ingelheim global company adversely affect geopo litical development significant risk arise factor geopolitical tension change economic political condition impact production site sale market global geopolitical development particular connection rus sian war aggression ukraine constant observation boehringer ingelheim appropriate measure address generally concrete low risk maintain successful global business take early stage credit countryspecific risk boehringer ingelheim expose credit countryspecific risk result international business activity portfolio trade account receivable trade count payable identify extraordinary risk group usual level industry compare previous year apply possible default risk receivables largely hedge economic political risk continue carefully track credit countryspecific risk position respond negative change timely manner risk consider moderate regard concrete financial investment shareholding risk group pursue conservative investment strategy management financial asset primary objective longterm preservation real value reflect orien tation portfolio mainly comprise money market bond investment sult concrete controllable limited level risk financial investment net book value strategic investment relate company affect market business circumstance lead high level volatility fair market value concrete risk cover respective impairment consolidate financial statement boehringer ingelheim annual report legal risk business activity group expose legal risk distinction regulatory liability patentprotection risk regulatory risk boehringer ingelheim expose risk arise legal dispute proceeding official investigation legal administrative decision ongoing future proceeding predict regard resultant risk abstract high addition employee boehringer ingelheim regularly train compliance regulatory require ment order minimize probability risk occur liability risk marketing sale pharmaceutical expose potential product liability risk boehringer ingelheim currently product liability insurance company risk profile absolutely guarantee insurance coverage main taine reasonable cost acceptable condition sufficient protect boehringer ingelheim claim loss potential claim loss case foreseeable product liability insurance cover partially cover concrete liability risk remain risk exposure cover provision moderate risk group furthermore product liability claim tie substantial financial resource manage ment capacity detrimental company image event market consid ers medicine unsafe ineffective result unexpected effect abstract moderate risk patent protection risk protection innovation trademark patent right particular importance boehringer ingelheim researchdriven biopharmaceutical company commercial pro tective right increasingly target attack breach take necessary precaution allow detect threat early stage commence appropriate countermeasure defend legal position legal mean available factor regard concrete moderate risk information technology risk boehringer ingelheim use global networked system core area operation busi ness production process internal external communication make use cloudbase thirdparty system service system process store transmit confidential personal datum availability integrity confidentiality system datum process highly significant external cyber attack manipulation system result loss information expertise temporary interruption business production process risk consider high concrete view continuously evolve global environment grow frequency cyber attack risk threat attack increase year people increa ingly work home employee access sensitive datum secure environment group management report report opportunitie risk boehringer ingelheim counter risk mean continuous process analysis improvement preventive reactive measure helps identify ward current threat minimize potential damage production environmental risk quality management system compliance process continuously optimize close cooperation relevant authority order ensure compliance cgmp standard current good manufacturing practice risk area continue high significance group classify abstract boehringer ingelheim implement riskmitigate measure past year order counter covidspecific threat production activ itie include physical segregation production team possible obligation wear mask increase supply disinfectant inhouse initiative test covid status employee order guarantee supply product market implement measure guarantee reliable highquality supply customer addition supplier man agement procurement involve build internal standby capacity overall represent concrete moderate risk risk area environment health safety sustainability ehss preemp tively minimize ensure global adherence high safety standard appropriate emer gency plan draw possible incident kind practice sub jecte comprehensive quality test regular interval result measure risk class concrete limited personnel risk company boehringer ingelheim expose demographic change sultant risk affect lack appropriately qualified personnel potential risk substantial impact company business activity clude longterm planning process year gain strategic significance result boehringer ingelheim counter risk mean comprehensive personnel concept present group opportunity context global personnel management regardless ethnic background gender religion offer company employ ees development opportunity base professional ability social skill personal titude willingness responsibility accordance need company view measure describe risk regard concrete moderate boehringer ingelheim expose human resource risk result covid pandemic pathogen spread significant impact outside production activity company closely monitor situation vicinity site emphasize work home extent necessary digital application inperson meeting view measure consid ere concrete moderate risk boehringer ingelheim annual report industryspecific risk boehringer ingelheim expose business risk specific pharmaceutical indus try risk materialize past financial year increa ingly important boehringer ingelheim effect continue class abstract high addition loss exclusivity product establish market risk associate development registration new medicine industry specific risk increasingly include change restrictive requirement relate pricing reimbursement sale market frequently price pharmaceutical product subject state monitoring regulation price pressure state imbursement system cheap generic drug boehringer ingelheim keep close eye change respective sale market take appropriate measure response current development net book value individual balance sheet item expose change market business condition change fair value event necessary pairment significant noncash impact earning balance sheet ratio apply particular intangible asset include goodwill essentially stem past company acquisition relevant risk assess take account preparation consolidated financial statement overall statement risk situation current perspective aware risk conjunction risk lead lasting impairment company net asset financial earning posi tion jeopardize continued existence boehringer ingelheim group management report report expect development report expect development boehringer ingelheim look successful financial year achieve objective term contribution wellbee patient livestock pet term key financial datum exceed term expect growth despite volatile environment able ensure company sustainable development profitable growth influential development influence come financial year present challenge expect general inflation remain level recent year despite countermeasure take central bank high energy price result war ukraine ease medium term particularly europe impact china away zerocovid policy initiate end fully assess continue expect china limited global presence subdue national development continue look confidence plan improve live patient imal innovation achieve sustainable growth outlook come financial year remain difficult current economic situation great uncertainty come year potential impact govern ment economic recovery sustainability support program respective government budget plan result policy shift relate innovative medicine expect moderate market growth prescription pharmaceutical exclude covid medication observe increase global institutional effort low price medicinal product view development financial ability act regard sus tainable growth innovation remain great importance expect moderate market growth new financial year animal health sector research innovation particularly important business ner intend continue provide customer innovative solution boehringer ingelheim new launch pet livestock segment enable growth magnitude market priority biopharmaceutical business area supply market product contract manufacturing business partner utilization largescale cell culture facility vienna continue focus expect boehringer ingelheim achieve slight yearonyear increase net sale comparable basis adjust currency extraordinary effect consistently high expenditure increase line strategic focus continue drive growth flow new product achieve goal obtain external innovation partner ship continue actively pursue strategy invest exter nal close investigation therapeutic benefit associate prospect success flow innovative medicine research development pipeline show short medium longterm growth potential expect increase investment new medicine intend reach new milestone research velopment individual market approval boehringer ingelheim annual report addition patent expiry major challenge face researchdriven pharmaceutical industry increase investment big hurdle increase cost associate product approval particular note previously mention grow cost pressure healthcare system year pandemic searchdriven pharmaceutical company display unprecedented level network energy develop solution interest patient extremely quickly prove societal value research innovation sustainable step require involve politician support stakeholder group pharmaceutical company contribution value overall economic add value increase efficiency healthcare system continue appropriately reward animal health research likewise require major investment preventive research diagnostic option conjunction long planning development cycle new product grow public cost pressure mean business predictable require quickly recognize seize opportunity human pharma animal health continuously monitor adjust cost strategy implement measure business area accelerate speed response change reduce complexity organization optimize cost base way create potential capital expenditure securing company longterm success expect boehringer ingelheim achieve slight improvement operating income despite increase level investment research development comparable basis adjust currency extraordinary effect boehringer ingelheim develop therapy fundamentally change life today gen eration come traditional family enterprise ensure competitiveness longterm entrepreneurial independence confident achieve ambitious target business area thank great innovative strength rest comprehensive portfolio prospective product global presence support highly qualified motivated employeesconsolidate financial statement verview select consolidated company consolidate balance sheet consolidate profit loss statement consolidate cash flow statement statement change group equity ote consolidated financial statement independent auditor report boehringer ingelheim annual report overview select consolidated company boehringer sohn ingelheim rhein boehringer ingelheim vetmedica gmbh ingelheim rhein argentina italy taiwan germany boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim corporate argentina buenos aire italia spa milan taiwan ltd taipei center gmbh ingelheim rhein australia japan thailand boehringer ingelheim gmbh ingelheim rhein boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim pharma australia pty ltd north ryde japan ltd tokyo thailand limited bangkok gmbh ingelheim rhein boehringer ingelheim microparts belgium mexico usa gmbh dortmund boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim animal health boehringer ingelheim venture fund belgium brussels mxico mexico city usa inc wilmington delaware gmbh ingelheim rhein boehringer ingelheim veterinary boehringer ingelheim medicine belgium evergem netherland biopharmaceutical gmbh ingelheim rhein boehringer ingelheim animal health brazil netherlands alkmaar boehringer ingelheim middle east africa gmbh boehringer ingelheim animal health ingelheim rhein brasil ltda paulo new zealand boehringer ingelheim boehringer ingelheim animal health therapeutic gmbh canada new zealand limited auckland ochsenhausen boehringer ingelheim animal health gmbh canada inc burlington philippines ingelheim rhein boehringer ingelheim animal health china philippines inc makati city nanchang boehringer ingelheim animal health ltd nanchang puerto rico boehringer ingelheim animal boehringer ingelheim animal health health shanghai ltd puerto rico llc barceloneta shanghai boehringer ingelheim animal south africa health operation china ltd taizhou boehringer ingelheim animal health boehringer ingelheim vetmedica south africa pty ltd midrand china ltd taizhou gauteng denmark south korea boehringer ingelheim animal health boehringer ingelheim animal health denmark copenhagen korea ltd seoul france spain boehringer ingelheim animal health boehringer ingelheim animal health france lyon espaa barcelona great britain boehringer ingelheim animal health limit bracknell distribution production research development consolidate financial statement overview select consolidated company boehringer sohn grundstcksverwaltung gmbh ingelheim rhein boehringer ingelheim international gmbh ingelheim rhein argentina czech republic japan south africa boehringer ingelheim boehringer ingelheim spol sro nippon boehringer ingelheim ingelheim pharmaceutical buenos aires prague ltd tokyo proprietary ltd midrand gauteng boehringer ingelheim seiyaku australia denmark yamagata south korea boehringer ingelheim pty ltd boehringer ingelheim danmark boehringer ingelheim korea ltd north ryde copenhagen mexico seoul boehringer ingelheim mexico austria ecuador mexico city spain boehringer ingelheim vetmedica boehringer ingelheim rcv boehringer ingelheim del ecuador boehringer ingelheim espaa guadalajara gmbh vienna cia ltda quito barcelona boehringer ingelheim promeco boehringer ingelheim pharma mexico city gesellschaft mbh vienna finland sweden lou gin eit lst mol hku eso oringer ingelheim finland netherlands sto hin lmer ingelheim aktiebolag viratherapeutics gmbh rum boehringer ingelheim alkmaar france switzerland belgium new zealand boehringer ingelheim france sas boehringer ingelheim schweiz boehringer ingelheim scomm paris boehringer ingelheim ltd gmbh basel brussels auckland nbetherapeutics basel great britain amal therapeutic geneva brazil norway boehringer ingelheim ltd boehringer ingelheim brasl bracknell boehringer ingelheim norway taiwan qumica farmaceutica ltda asker paulo boehringer ingelheim taiwan ltd greece taipei peru canada boehringer ingelheim hellas single member athens boehringer ingelheim peru sac thailand boehringer ingelheim canada ltd lima toronto boehringer ingelheim thai ltd hong kong bangkok philippines chile boehringer ingelheim hong kong ltd hong kong boehringer ingelheim philippines trkiye boehringer ingelheim ltda inc makati city santiago chile boehringer ingelheim ila ticaret india istanbul poland china boehringer ingelheim india private ltd mumbai boehringer ingelheim usa boehringer ingelheim shanghai warsaw pharmaceuticals ltd shanghai boehringer ingelheim indonesia pharmaceuticals inc boehringer ingelheim boehringer ingelheim indonesia portugal wilmington delaware biopharmaceuticals china ltd jakarta boehringer ingelheim portugal lda boehringer ingelheim fremont inc shanghai lisbon wilmington delaware boehringer ingelheim china israel boehringer ingelheim usa investment ltd shanghai russia corporation wilmington delaware ehealth technology shanghai boehringer ingelheim israel ltd ltd shanghai tel aviv ooo boehringer ingelheim moscow vietnam colombia italy saudi arabia boehringer ingelheim animal health vietnam limited liability company boehringer ingelheim boehringer ingelheim italia spa boehringer ingelheim saudi arabia chi minh city santa bogot milan trading riyadh boehringer ingelheim vietnam ltd bidachem spa fornovo giovanni chi minh city croatia serbia boehringer ingelheim zagreb doo boehringer ingelheim serbia doo zagreb beograd belgrade boehringer ingelheim annual report consolidate balance sheet asset million eur note intangible asset tangible asset financial asset fix asset inventory account receivable asset security cash cash equivalent current asset prepaid expense defer tax asset exceed plan asset total asset equity liability million eur note shareholder capital group reserve balance sheet currency conversion difference equity attributable parent company noncontrolle interest group equity difference capital consolidation provision account payable loan liability defer income defer tax liabillitie total equity liability explanation relevant section note consolidated financial statement consolidate financial statement consolidate balance sheet consolidate profit loss statement consolidated profit loss statement million eur note net sale change finish good work process work capitalize operating income total revenue cost material personnel expense amortization intangible asset depreciation tangible asset operating expense operate income financial income hold income income taxis income taxis income taxis net income noncontrolle interest group profit explanation relevant section note consolidated financial statement legal requirement shareholder personal taxis arise group business activity show withdrawal group reserve boehringer ingelheim annual report consolidate cash flow statement million eur income taxis include noncontrolle interest amortization depreciation writedown reversal writedown intangible tangible financial asset change provision pension similar obligation include change plan asset change provision noncash income expense gain disposal consolidate company gain loss disposal fix asset grant receive change inventory change account receivable asset relate investing financing activity change account payable liability relate investing financing activity interest income interest expense income investment income expense income taxis income taxis pay cash flow operating activity payment acquire intangible fix asset payment acquire tangible fix asset payment acquire financial fix asset payment acquire plan asset proceed disposal intangible fix asset proceed disposal tangible fix asset proceed disposal financial fix asset proceed disposal consolidated entity interest receive income dividend cash flow investing activity cash receipt grant interest pay proceed capital contribution minority shareholder cash payment shareholder parent company proceed loan cash repayment loan cash flow financing activity consolidate financial statement consolidated cash flow statement statement change group equity consolidated cash flow statement continue million eur change financial fund cash relevant transaction change financial fund exchange rate movement valuation adjustment financial fund financial fund line contain shareholder personal taxis arise group business activity accord legal requirement include group tax expense cash cash equivalent security current asset source fund use fund statement change group equity balance sheet equity currency attributable non shareholder group conversion parent control million eur capital reserve difference company interest group equity balance withdrawal net income reduction recognition defer tax liability recognize directly equity change consolidate company currency effect balance withdrawal net income change consolidate company currency effect balance shareholder capital consist equity boehringer sohn boehringer sohn grundstcksverwaltung gmbh shareholders capital consist limited partner capital contribution shareholder personal taxis arise group business activity show withdrawal group reserve boehringer ingelheim annual report note consolidated inancial statement principle method general principle consolidate financial statement boehringer sohn financial year prepare accordance section german commercial code handelsgesetzbuch hgb line legal requirement prepare consolidated financial statement section seq hgb accordance section hgb consolidated financial statement consist consolidated balance sheet consolidated profit loss statement note consolidated financial statement consolidated cash flow statement statement change group equity consolidated financial statement prepare euro accordance section conjunction section hgb improve clarity transparency consolidated financial statement subtotal add con solidate profit loss statement furthermore individual item consolidate balance sheet consolidat profit loss statement combine item present explain separately note consolidated financial statement additional disclosure require individual item find note consolidated financial statement registry information parent company register boehringer sohn headquarters ingelheim rhein commercial register mainz district court number hra information group consolidated companies parent company boehringer ingelheim group boehringer sohn ingelheim rhein boehringer ingelheim rhein sole unlimited partner company hold participation subsidiary boehringer ingelheim group boehringer ingelheim group consist total affiliated company germany abroad subsidiary include consolidated financial statement boehringer sohn consolida tion rules boehringer sohn grundstcksverwaltung gmbh special purpose entity boehringer sohn bear majority risk reward economic term boehringer sohn hold majority voting right subsidiary directly indirectly accordance section hgb subsidiary include consolidation reporting year individually collectively insignificant group net asset financial earning position total consolidated financial statement note consolidated financial statement sale equity net income year subsidiary include consolidation account percent aggregate group financial statement total subsidiary ongo ing restriction control term article association accordance section hgb company consolidate total number affiliate company decrease compare previous year company found company lose separate legal identity merger affiliated company liquidate affiliated company sell follow subsidiary exempt report disclosure obligation pursuant section hgb boehringer ingelheim gmbh ingelheim rhein boehringer ingelheim europe gmbh ingelheim rhein boehringer ingelheim finanzierung gmbh ingelheim rhein boehringer ingelheim secura versicherungsvermittlung gmbh ingelheim rhein boehringer ingelheim grundstcksgmbh ingelheim rhein boehringer ingelheim beteiligung gmbh ingelheim rhein boehringer ingelheim animal health france participation gmbh ingelheim rhein boehringer ingelheim finanzinvest gmbh ingelheim rhein boehringer ingelheim gmbh make use exemption report disclosure obligation pursu ant section hgb disclosure require accordance section hgb provide shareholder meeting boehringer ingelheim gmbh resolve accordance section german act limit liability company gesetz betreffend die gesellschaften mit beschrnkter haftung gmbhg set proportion woman management target achieve end financial year accordance section gmbhg manage director boehringer ingelheim gmbh decide set proportion woman management level manage director second management level manage director target achieve end financial year follow subsidiary exempt report disclosure obligation pursuant section hgb boehringer sohn ingelheim rhein boehringer sohn grundstcksverwaltung gmbh ingelheim rhein boehringer ingelheim pharma gmbh ingelheim rhein boehringer ingelheim participate joint venture include consolidated financial state ment proportionate method equity method material furthermore boehringer ingelheim hold interest associate company recognize equity method lack significance equity method balance sheet total consolidated profit loss affect percent boehringer ingelheim annual report consolidation method inventory fix asset receivables liability income expense item transaction company include consolidation eliminate debt consolidation procedure accordance section hgb procedure eliminate intercompany profit accordance section hgb income expense consolidation procedure accordance section hgb revaluation method apply include subsidiary consolidation time accordance section hgb company include consolidation time respective date company subsidiary book value share hold parent company offset correspond equity subsidiary equity carry fair value asset liability prepay expense defer income special reserve include consolidated financial statement time consolidation remain positive bal ance record goodwill remain negative balance record difference capital consolidation currency translation asset liability result foreign currency transaction translate average spot exchange rate balance sheet date realization principle section conjunction section half sentence hgb historical cost principle section conjunction section sentence hgb apply item remain term year consolidated financial statement financial statement foreign subsidiary domicile state outside eurozone denominate foreign currency convert euro modify closing rate method accordance section hgb modify closing rate method asset liability item annual financial statement prepare foreign currency translate euro average spot exchange rate balance sheet date exception equity translate historical rate item include profit loss statement translate euro annual average rate result translation difference report consoli date equity reserve balance sheet currency conversion difference exchange rate group important currency change follow report year basis eur spot rate average rate dollar japanese yen chinese renminbi consolidated financial statement note consolidated financial statement accounting policy fix asset acquire intangible asset property plant equipment carry cost scheduled straightline amortiza tion depreciation determine consideration technical economic circumstance base follow useful life goodwill year intangible asset year building year technical facility machine year facility operating equipment year straightline depreciation amortization consolidated financial statement additional write down record reflect impairment value asset consider permanently impaired manufacturing cost include material labor manufacturing cost appropriate portion material labor overhead depreciation fix asset extent cause production manufacturing cost include financing cost capitalize intangible asset finite useful life financial asset primarily include investment security shareholder right loan carry low cost fair market value impair event reason impairment loss recognize previous nancial year long applicable corresponding reversal record current asset prepay expense defer income exceeding plan asset inventory carry low cost fair market value raw material consumable supply capitalize low average acquisition price fair market value balance sheet date finish good work progress measure manufacturing cost basis individual calculation take account directly attributable cost material direct labor cost special direct cost appropriate share material production overhead cost productionrelate depreciation good resale measure lower acquisition cost fair market value boehringer ingelheim annual report identifiable risk inventory arise aboveaverage storage period diminish marketability low replacement cost take account record appropriate valuation adjustment measurement carry lossfree deduction expect sale price reflect cost incur receivables asset recognize cost allowance specific risk general credit risk low interest noninterestbeare receivables term year discount security classify current asset solely include security recognize low cost applicable value result stock exchange market price report date cash cash equivalent consist cash balance bank check recognize low cost fair market value prepay expense record accordance section hgb include expense pay advance respect define period time balance sheet date defer income record accordance section hgb include proceed represent income respect define period time balance sheet date fair market value pension plan asset correspond present value pension obligation set accord german gaap exceeding plan asset capitalize separately group reserve group reserve include retain earning consolidate subsidiary prior current year consoli dation entry affect earning difference capital consolidation difference capital consolidation report december result business swap boehringer ingelheim consumer healthcare business sanofis animal health business complete january result difference capital consolidation million eur difference amortize estimate period year remain balance difference amount million eur cember difference capital consolidation primarily influence current year release million eur income release difference arise capital consolidation include operate income release correspond amortization asset acquire company identify purchase price allocation previously recognize company balance sheet consolidate financial statement note consolidated financial statement provision tax provision provision include uncertain liability expect loss executory contract carry require settle obligation base reasonable prudent commercial judgment include future cost price increase provision remain maturity year discount matchedterm average market interest rate case pension provision interest rate result average market interest rate year case provision average market inter est rate seven year accordance rckstellungsabzinsungsverordnung german regulation discount provision environmental protection measure case expect result permanent burden relevant pro vision calculate basis perpetual annuity take consideration cost price increase interest effect current cost adjust inflation basis average rate change producer price index industrial product introduction euro ultimate forward rate ufr provide european insurance occupational pension authority eiopa discount account payable loan account payable loan recognize settlement defer taxis calculate defer taxis arise temporary quasipermanent difference carry amount asset liability prepay expense defer income commercial balance sheet carrying amount tax purpose tax loss carryforward amount result tax benefit expense time difference reverse measure tax rate specific respective consolidated company defer tax balance discount difference consolidation measure accordance section hgb measure companyspecific tax rate applicable time expect reversal difference defer tax asset loss carryforward take account likely year defer tax asset liability report offset boehringer ingelheim annual report note consolidated balance sheet intangible asset acquire concession advance million eur similar right goodwill payment total acquisition manufacturing cost balance currency conversion difference change consolidate company addition disposal reclassification balance currency conversion difference change consolidate company addition disposal reclassification balance accumulate amortization balance currency conversion difference change consolidate company addition writeup disposal reclassification balance currency conversion difference change consolidate company addition writeup disposal reclassification balance book value book value consolidate financial statement note consolidated financial statement tangible asset advance technical facility payment land facility operate construction million eur building machine equipment progress total acquisition manufacturing cost balance currency conversion difference change consolidate company addition disposal reclassification balance currency conversion difference change consolidate company addition disposal reclassification balance accumulate depreciation balance currency conversion difference change consolidate company addition writeup disposal reclassification balance currency conversion difference change consolidate company addition writeup disposal reclassification balance book value book value boehringer ingelheim annual report financial asset investment investment loan affiliate related related investment million eur company companies company security loan total acquisition manufacturing cost balance currency conversion difference change consolidate company addition disposal reclassification balance currency conversion difference change consolidate company addition disposal reclassification balance accumulate depreciation balance currency conversion difference change consolidate company addition writeup disposal reclassification balance currency conversion difference change consolidate company addition writeup disposal reclassification balance book value book value previous year loan item include loan shareholder consolidated financial statement note consolidated financial statement inventory million eur raw material supply unfinished good finish good good resale advance payment supplier account receivable asset residual term residual term million eur year year trade account receivable receivables affiliate company receivables related company asset receivables affiliated company exclusively consist receivables loan receivables related company primarily consist trade account receivable asset include receivables shareholder million eur previous year million eur provision million eur pension provision similar obligation tax provision provision boehringer ingelheim annual report provision pension similar obligation provision pension similar obligation determine basis actuarial calculation project unit credit method take account future adjustment salarie pension addition local biometric datum germany example mortality table publish prof klaus heubeck adjust groupspecific death probability invalidity rate pension obligation signifi country calculate basis follow actuarial parameter december germany usa discount rate salary increase pension increase discount rate determine reference average market rate year maturity accordance german regulation discount provision march interest rate discount significant foreign pension obligation usa determine comparable parameter line german regulation discount provision march difference calculate accordance section hgb amount million eur previous year mil lion eur asset intend solely cover pension similar obligation unavailable creditor plan asset define section sentence hgb measure fair market value essentially derive stock market price offset underlie pension similar obligation fair market value plan asset balance sheet date million eur relate pension obligation similar obligation million eur tax provision tax provision include provision double taxation risk result follow implementation action plan organisation economic cooperation development oecd international initiative know action plan base erosion profit shift bep consolidated financial statement note consolidated financial statement provision provision mainly include provision discount guarantee personnelrelate provision provision outstanding invoice provision litigation legal claim compensation damage account payable loan residual term residual term thereof million eur year year year year bank loan account payable thereof trade account payable advance payment receive account payable affiliate company account payable relate company liability thereof taxis million eur social security liability million eur previous year liability secure mortgage similar collateral right balance sheet date end year liability shareholder amount million eur previous year million eur present liability account payable affiliate company include loan amount million eur previous year million eur trade account payable amounting million eur previous year million eur boehringer ingelheim annual report note consolidated profit loss tatement structure consolidated profit loss statement base total cost format taxis include operating expense net sale business million eur human pharma animal health biopharmaceutical contract manufacturing sale discontinue operation region million eur americas europe asia australia africa aaa operating income operating income include foreign currency gain million eur previous year million eur cost material million eur cost raw material supply good resale expenditure service consolidate financial statement note consolidated financial statement personnel expense million eur wage salarie social benefit retirement benefit thereof retirement benefit interest effect measurement provision pension similar obligation show financial income average headcount production marketing sale research development administration apprentice amortization intangible asset depreciation tangible asset amortization intangible asset depreciation tangible asset include impairment loss million eur previous year million eur operating expense operating expense include foreign currency loss million eur previous year million eur furthermore operating expense include expense research development medical study market freight expense party repair service cost legal risk restructuring administrative expen contribution fee taxis boehringer ingelheim annual report financial income million eur interest expense similar expense amortization loss disposal financial fix asset shortterm investment income investment security longterm loan interest income similar income interest expense similar expense item include interest result provision pension similar obligation provision million eur previous year million eur interest expense similar expense million eur previous year million eur gain loss plan asset interest expense relate pension similar obligation offset accordance section sentence hgb total million eur interest expense plan asset million eur interest expense relate pension similar obligation include interest expense similar expense hold income million eur writedown financial asset writeup financial asset income relate company thereof disposal relate company income taxis million eur current income taxis defer taxis current income taxis primarily include corporation trade tax expense consolidated company consolidate financial statement note consolidated financial statement total balance defer tax asset balance sheet date amount million eur previous year million eur defer tax asset primarily arise difference carry amount provision pension obligation discount taxable goodwill intangible asset inventory tangible asset defer tax liability million eur previous year million eur record primarily relate difference carry amount intangible asset tangible asset inventory provision net income net income positively influence nonperiod income primarily reversal provision million eur previous year million eur negatively influence nonperiod expen particular additional expense relate provision million eur previous year million eur note consolidated cash flow statement consolidate cash flow statement show change financial fund boehringer ingelheim group result cash inflow outflow report year financial fund contain cash cash equivalent secu ritie convert cash shortterm change balance sheet item affiliate company include translate average rate year balance sheet financial fund carry spot rate effect exchange rate change financial fund show separately financial fund december comprise follow item million eur cash cash equivalent security classify current asset financial fund include million eur restrict fund balance sheet date boehringer ingelheim annual report disclosure contingent liability million eur liability guarantee warranty grant security thirdparty liability contingent liability assume careful risk assessment connection business activity affiliate company risk contingent liability assess low base information available balance sheet date risk probability availment reasonable balance sheet date record provision financial commitment offbalance sheet transaction million eur rental lease obligation residual financial commitment rental lease obligation million eur previous year million eur relate longterm rental agreement subsidiary include consolidation purpose lease agreement low capital commitment compare buy property absence resale risk risk arise term lease possible continue utilize property fully indication time residual financial commitment include investment future effect cash flow million eur previous year million eur derivative financial instrument valuation unit extensive international structure boehringer ingelheim group highly dependent development world currency interest rate hedge risk particularly emerge delivery good service finance currency forwards option generally currency risk interest rate swap option interest rate risk use derivative financial instrument organizational process set internal guideline strict separation trading processing documentation control consolidated financial statement note consolidated financial statement risk position regularly track analyzed measure special groupwide financial report position enter periodically reevaluate monitor fair value derivative financial instrument calculate generally accept market valuation method currency forward base present value method take account market datum balance sheet date provision million eur recognize currency forward include hedge accounting negative fair value currency balance sheet date line imparity principle positive fair value currency recognize balance sheet date derivative financial instrument include hedge accounting valuation unit follow nominal value fair value million eur foreign exchange forward contract extent requirement hedge account foreign currency forward exchange contract highly probable forecast transaction accordance section hgb meet foreign currency forward exchange contract recognize balance sheet line net hedge presentation method follow accounting policy apply recognition valuation unit accordance section hgb economic hedge account financial statement use valuation unit valuation unit recognize foreign currency base net highly probable forecast transaction currency forwards match forecast net cash flow term maturity nominal foreign currency macro hedge highly probable forecast transaction income outgoing payment plan sale purchase derive company plan expost analysis planning show plan transaction highly probable oppose change value hedge item hedge instrument fully offset critical term aturity nominal foreign currency match effective hedge assume prospectively retrospectively critical term match method exclusively measure prospective retrospective effectiveness hedge excess amount hedging transaction include valuation unit boehringer ingelheim annual report december hedge highly probable forecast net cash flow recognize follow january december net cash flow million eur foreign exchange forward contract million eur nominal value nominal value fair value usd usd usd jpy jpy jpy aud aud aud mxn mxn mxn cad cad cad gbp gbp gbp january december net cash flow million eur foreign exchange forward contract million eur nominal value nominal value fair value usd usd usd jpy jpy jpy aud aud aud mxn mxn mxn cad cad cad gbp gbp gbp january december usd january jpy net cash flow million eur foreign exchange forward contract million eur nominal value nominal value fair value usd usd usd jpy jpy jpy january february net cash flow million eur foreign exchange forward contract million eur nominal value nominal value fair value usd usd usd consolidated financial statement note consolidated financial statement furthermore december valuation unit foreign currency receivable recognize follow receivables million eur foreign exchange forward contract million eur nominal value nominal value fair value rub rub rub december valuation unit foreign currency receivables result loan recognize follow receivables million eur foreign exchange forward contract million eur nominal value nominal value fair value cad cad cad chf chf chf cny cny cny mxn mxn mxn thb thb thb twd twd twd usd usd usd hedge foreign currency risk correlate relative change exchange rate plan ne date realization date forecast transaction currency appreciate depreciate euro foreign currency risk million eur hedge research development expense million eur research development expense noncapitalized research development expense include item cost associate clinical study boehringer ingelheim annual report total auditor fee total fee charge group auditor financial year amount million eur million eur relate audits financial statement million eur assurance service million eur tax adviso service million eur service subsequent event end financial year aware event material significance group lead reappraisal net asset financial earning position shareholding list company include consolidated financial statement list shareholding present cordance section hgb include audit consolidated financial statement submit german federal gazette ingelheim rhein february boehringer board manage director hubertus von baumbach carinne knochebrouillon michel pairet jean scheftsik szolnok michael schmelmer consolidated financial statement independent auditor report independent auditor report boehringer sohn ingelheim rhein qualified audit opinion consolidated financial statement audit opinion group management report audit consolidated financial statement boehringer sohn ingelheim rhein subsidiary group comprise consolidated balance sheet december consolidated profit loss statement cash flow statement statement change group equity financial year january december note consolidated financial statement include recognition measurement policy present addition audit group management report boehringer sohn financial year january december opinion basis knowledge obtain audit effect matter describe section basis qualified audit opinion consolidated financial statement audit opinion group management report accompany consolidated financial statement comply material respect requirement german commercial law true fair view asset liability financial position group december financial performance financial year january december compliance german legally require accounting principle accompany group management report provide appropriate view group position material respect group management report consistent consolidated financial statement complie german legal requirement appropriately present opportunity risk future development pursuant section sentence hgb handelsgesetzbuch german commercial code declare qualification audit opinion consolidated financial statement mention audit lead reservation relate legal compliance consolidated financial statement group management report basis qualified opinion consolidated financial statement audit opinion group manage ment report contrary section number letter hgb total remuneration grant member member board manage director pension provision recognize recognize member board manage director disclose note consolidated financial statement conduct audit consolidated financial statement group management report accordance section hgb compliance german generally accept standard financial statement audits promulgate institut der wirtschaftsprfer institute public auditor germany idw responsibility requirement principle describe auditor responsibility audit consolidated financial statement group management report section auditor report inde pendent group entity accordance requirement german commercial professional law fulfil german professional responsibility accordance requirement believe audit evidence obtain sufficient appropriate provide basis opinion consolidate financial statement group management report boehringer ingelheim annual report information management responsible information information comprise annual report exception audit consolidated financial statement group management report auditor report opinion consolidate financial statement group management report cover information consequently express opinion form assurance conclusion thereon connection audit responsibility read information consider information materially inconsistent consolidated financial statement group management report audit content knowledge obtain audit appears materially misstate responsibility management consolidated financial statement group management report management responsible preparation consolidate financial statement comply material respect requirement german commercial law consolidated financial statement compli ance german legally require accounting principle true fair view asset liability financial position financial performance group addition management responsible internal control accordance german legally require accounting principle determine necessary enable preparation consolidated financial statement free material misstatement fraud fraudulent financial reporting misappropriation asset error prepare consolidated financial statement management responsible assess group ability continue go concern responsibility disclose applicable matter relate go concern addition responsible financial reporting base go concern basis accounting provide actual legal circumstance conflict therewith furthermore management responsible preparation group management report provide appropriate view group position material respect consistent consolidated financial statement complie german legal requirement appropriately present opportunity risk future development addition management responsible arrangement measure system consider necessary enable preparation group management report accordance applicable german legal requirement able provide sufficient appropriate evidence assertion group management report consolidate financial statement independent auditor report auditor responsibility audit consolidated financial statement group management report objective obtain reasonable assurance consolidated financial statement free material misstatement fraud error group management report provide appropriate view group position material respect consistent consolidated financial statement knowledge obtain audit complie german legal requirement appro priately present opportunity risk future development issue auditor report include opinion consolidate financial statement group management report reasonable assurance high level assurance guarantee audit conduct accordance section hgb compliance german generally accept standard financial statement audits promulgate institut der wirtschaftsprfer idw detect material misstatement misstatement arise fraud error consider material individually aggregate reasonably expect influence economic decision user take basis consolidated financial statement group management report exercise professional judgment maintain professional skepticism audit identify assess risk material misstatement consolidated financial statement group management report fraud error design perform audit procedure responsive risk obtain audit evidence sufficient appropriate provide basis opinion risk detect material misstatement result fraud high risk detect material misstate ment result error fraud involve collusion forgery intentional omission misrepresentation override internal control obtain understand internal control relevant audit consolidate financial statement arrangement measure system relevant audit group management report order design audit procedure appropriate circumstance purpose express opinion effec tiveness systems evaluate appropriateness accounting policy management reasonableness estimate management relate disclosure conclude appropriateness management use go concern basis accounting base audit evidence obtain material uncertainty exist relate event condition cast significant doubt group ability continue go concern conclude material uncertainty exist require draw attention auditor report relate disclosure consolidate finan cial statement group management report disclosure inadequate modify respective opinion conclusion base audit evidence obtain date auditor report future event condition cause group cease able continue go concern evaluate overall presentation structure content consolidated financial statement include disclosure consolidated financial statement present underlying transaction event manner consolidated financial statement true fair view asset liability financial position financial performance group compliance german legally require accounting principle boehringer ingelheim annual report obtain sufficient appropriate audit evidence financial information entity business activity group express audit opinion consolidate financial statement group management report responsible direction supervision performance group audit remain solely responsible audit opinion evaluate consistency group management report consolidate financial statement conformity german law view group position provide perform audit procedure prospective information present management group management report basis sufficient appropriate audit evidence evaluate particular significant assumption management basis prospective information evaluate proper derivation prospective information assumption express separate opinion prospective information assumption basis substantial unavoidable risk future event differ materially prospective information communicate charge governance matter plan scope time audit significant audit finding include significant deficiency internal control identify audit frankfurt main february kpmg wirtschaftsprfungsgesellschaft original german version sign sign kneisel sign bernau wirtschaftsprfer wirtschaftsprferin german public auditor german public auditor consolidated financial statement independent auditor report boehringer ingelheim annual report comparison balance sheet financial data asset december million eur intangible asset tangible asset financial asset fix asset inventory account receivable asset incl prepay expense defer taxis exceed plan asset financial fund current asset total asset equity liability december million eur shareholder capital group reserve incl balance sheet currency conversion difference group profit equity attributable parent company noncontrolle interest group equity difference capital consolidation provision incl defer taxis liability incl defer income total liability incl defer taxis defer income total equity liability summary select financial datum million eur net sale operating income operating income net sale income taxis income taxis net sale equity ratio cash flow operating activity financial fund personnel expense personnel expense net sale average number employee research development expense net sale investment tangible asset depreciation tangible asset imprint asset december boehringer sohn million eur binger strasse intangible asset ingelheim rhein tangible assets germany financial asset telephone fax fix asset inventory contact account receivable asset incl prepay expense corporate affair defer taxis exceed plan asset matthia reinig financial fund pressboehringeringelheimcom current asset boehringeringelheimcom total asset issue equity liability december boehringer sohn represent board manage director million eur hubertus von baumbach chair shareholder capital carinne brouillon michel pairet group reserve incl balance sheet currency conversion difference jean scheftsik szolnok michael schmelmer group profit concept design layout equity attributable parent company kommunikation gmbh mainz noncontrolle interest wwwstde group equity difference capital consolidation photo provision incl defer taxis andreas reeg seite urban zintel seite liability incl deferred income total liability incl defer taxis defer income copyright total equity liability boehringer sohn right reserve annual report summary select financial datum reproduce transmit form mean electronic photocopy permission write boehringer million eur sohn figure party annual net sale report base datum available time financial state ment draw operating income operating income net sale income taxis income taxis net sale equity ratio cash flow operating activity financial fund personnel expense personnel expense net sale average number employee research development expense net sale investment tangible asset depreciation tangible asset